FDA Forms Nicotine Steering Committee
The U.S. Food and Drug Administration (FDA) announced this week the formation of a new Nicotine Steering Committee that will be tasked with reevaluating and modernizing FDA’s policy and regulatory approach to nicotine and nicotine products to address tobacco addiction. This new committee formation follows the announcement from the FDA this summer for a new regulatory plan to lower the burden of tobacco-related disease and death through a more comprehensive approach to nicotine and tobacco.
The new Nicotine Steering Committee will first hold a public hearing for FDA to gather input on the public health, scientific, regulatory, and legal considerations related to nicotine replacement therapies (NRT) and their use in tobacco cessation. More information on the FDA’s regulatory approach related to tobacco is available here.